MedAustron is a pioneering center for ion therapy and research, specialized in advanced cancer treatment using protons and carbon ions, which is the most advanced form of radiation therapy. The center is one of only six comparable centers worldwide. 

RaySearch and MedAustron have been collaborating since 2012, when MedAustron was RaySearch's first customer for carbon ion therapy treatment planning in RayStation. In June 2019 MedAustron decided to replace other existing systems to exclusively use RaySearch software. Since then, the development teams at RaySearch and MedAustron have cooperated in a unique and close collaboration to develop both RayCare and RayCommand to meet MedAustron's complex requirements, with the treatment control system RayCommand serving as a seamless link between the treatment machine and the treatment planning and oncology information systems.

RaySearch products will improve radiotherapy at MedAustron
When MedAustron recently took first RayCare and then RayCommand in clinical use a big milestone was reached. The clinical benefits of connecting the three systems RayStation, RayCare and RayCommand are, among other things, streamlined workflows across the systems and automatically transferred data at key steps, important features contributing to enhanced operational efficiency as well as safety throughout the course of radiation treatment delivery.

Johannes Hopfgartner and Piotr Andrzejewski, Project Leads at MedAustron, say: "We are looking back to a more than a three-year project period together with the development teams of RaySearch. In this extensive and fruitful collaboration, we managed to translate the essential clinical needs of MedAustron into the current versions of RayCommand, RayCare and RayStation. We look forward to cooperating and contributing to the further development of the software suite." 

Markus Stock, Head of Medical Physics at MedAustron, says: "MedAustron has already been collaborating successfully with RaySearch for more than 10 years. The integrated, single software platform from RaySearch convinced us to extend our partnership on RayCare and the newly developed RayCommand. As a result, we are future-proof in terms of workflows in- and outside of the treatment rooms and we will continue to strive together for further improvements of safety, efficiency and productivity while keeping the patients in focus."

Johan Löf, founder and CEO, RaySearch, says: "We have had a close collaboration with MedAustron for many years and I am proud that this center, at the forefront of proton and carbon ion therapy in the world, has chosen to only use RaySearch software. I am also very pleased with the successful clinical launch of RayCommand and look forward to future collaboration and to continue exploring the possibilities within proton and carbon therapy together with the professional team at MedAustron."

About MedAustron
MedAustron is a cutting-edge center for ion therapy and research, specialized in advanced cancer treatment using protons and carbon ions. The center is one of only six comparable centers worldwide. It has more than 250 employees and operates as an independent outpatient clinic, but collaborates with other Austrian and international clinics, universities, and research institutes. MedAustron is located in Wiener Neustadt in Lower Austria. medaustron.at (https://www.medaustron.at/).

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.  

RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com (https://www.raysearchlabs.com/).

About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.

About RayCare
The RayCare®* oncology information system (OIS) is designed to support the many complex logistical challenges faced by today's oncology clinics. RayCare is closely integrated with RayStation®* and provides seamless access to all the powerful planning tools in RayStation and RayCommand®. The system efficiently coordinates activities in radiation therapy and offers advanced features for clinical workflow automation, and adaptive radiation therapy. RayCare responds to the demand from clinics for a more user-friendly and workflow-oriented information system that can support the cancer care of the future. 

About RayCommand
RayCommand®* treatment control system (TCS) is the link between the treatment machine and the treatment planning and oncology information systems. RayCommand coordinates and orchestrates the different systems involved, such as imaging systems, beam delivery systems and the patient support system. Effective coordination is critical in order to achieve safe and efficient patient treatments.

* Subject to regulatory clearance in some markets.